NRG-GY017

Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer

Principal Investigator

Jyoti Mayadev, MD

Status

Disease Site

Gynecologic [GY] Cervix

Phase

I

Developmental Therapeutics

No

Primary Objective

To determine whether differences in sequencing of atezolizumab and chemoradiation result in differential immune activation, as determined by clonal expansion of T cell receptor beta (TCRB) repertoires in peripheral blood on day 21.

Patient Population

Patients with locally advanced cervical cancer.

Target Accrual

40